Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
Author:
Jones Nick K12ORCID, Rivett Lucy12ORCID, Seaman Shaun3, Samworth Richard J4, Warne Ben156, Workman Chris7, Ferris Mark7, Wright Jo7, Quinnell Natalie7, Shaw Ashley1, Amory Amy, Baker Stephen, Bateman Emma, Begum Aklima, Begum Moushima, Bradley John, Brennan Michael, Burn Helen, Crofts Caroline, Chaudhry Afzal, Chaudhry Yasmin, Cooper Daniel J, Dawson Sharon, Dougan Gordon, Feather Renny, Free Louise, Friel Katie, Gildea Claire, Georgana Iliana, Grimwade Lizz, Gupta Ravi, Hall Susan, Hannan Sophie, Hayes James, Hosaja Aleksandra, Hosmillo Myra, Izuagbe Rhys, Jahun Aminu, James Lidia, Jardin Jill, Kingston Nathalie, Lear Sara, Lyons Paul A, Maxwell Patrick H, Mott Sue, Mugavin Sarah, Mwiya Joyce, Peacock Sharon, Nallattil Ravi Prakash, Oloyede Kazeem, Ouwehand Willem H, Page Elle, Perez Marina, Raine Tim, Routledge Matthew, Saunders Caroline, Smith Kenneth GC, Sparkes Dominic, Stafford Maria, Summers Charlotte, Tatsi Despiona, Thaventhiran James ED, Thomas Johnson Sharon, Török M Estée, Toshner Mark, Turner Lesley, Wall Kate, Watson Karis, Goodfellow Ian G8ORCID, Lehner Paul J156ORCID, Howes Rob9, Wright Giles7, Matheson Nicholas J15610ORCID, Weekes Michael P1611ORCID,
Affiliation:
1. Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom 2. Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom 3. Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom 4. Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, Cambridge, United Kingdom 5. Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom 6. Department of Medicine, University of Cambridge, Cambridge, United Kingdom 7. Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom 8. Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom 9. Cambridge COVID-19 Testing Centre and AstraZeneca, Anne McLaren Building, Cambridge, United Kingdom 10. NHS Blood and Transplant, Cambridge, United Kingdom 11. Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
Abstract
The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease.
Funder
Wellcome Trust Medical Research Council NHS Blood and Transplant EPSRC
Publisher
eLife Sciences Publications, Ltd
Subject
General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|